Month: June 2023

Hundreds of 1199SEIU health care workers staged a rally and sit to block 3rd avenue where some were arrested. They protested against health care cuts in Governor Kathy Hochuls budget on Medicare. Lev Radin | Lightrocket | Getty Images Medicare on Friday said it will allow pharmaceutical companies to publicly discuss the program’s historic drug
0 Comments
Sublingual immunotherapy, also known as allergy drops, is a form of disease-modifying allergy treatment similar to allergy shots. Instead of a shot, sublingual immunotherapy works as a liquid drop that is placed under the tongue. Sublingual: applied under the tongue Immunotherapy: therapy that uses substances to stimulate or suppress the immune system to help the
0 Comments
Treatment for: Duchenne Muscular Dystrophy Italfarmaco Group Completes FDA Submission of New Drug Application for Givinostat in Duchenne Muscular Dystrophy and Receives Priority Review MILAN, June 29, 2023–(BUSINESS WIRE)–Italfarmaco Group announced today that the U.S. Food and Drug Administration (FDA) has completed its filing review and accepted the company’s New Drug Application (NDA) for Givinostat.
0 Comments
Alice Wiseman, Director of Public Health for Gateshead and Association of Directors of Public Health Board Member, is one of many health experts across the UK helping to inform our upcoming Manifesto for Cancer Research and Care – an actionable set of policies aiming to transform cancer care in this country. Over the last 50 years,
0 Comments
In a recent article published in the Lancet Infectious Diseases, researchers performed a phase I randomized clinical trial between November 7, 2016, and October 30, 2018, in the United States of America (USA) to assess the safety and immunogenicity of an inactivated Zika virus vaccine candidate. Study: Safety and immunogenicity of a purified inactivated Zika virus vaccine
0 Comments
INDIANAPOLIS, June 26, 2023. Eli Lilly and Company (NYSE: LLY) announced today new phase 2 data from retatrutide, Lilly’s investigational molecule being studied for the treatment of obesity. At 24 weeks, retatrutide (1 mg, 4 mg, 8 mg or 12 mg) met the primary endpoint for the efficacy estimand in participants living with obesity or
0 Comments
Easy Sugar-Free Low-Carb Keto Lemon Curd Parfait – Diabetes Daily Learning Center Learning Center: LearningCenter Diabetes Daily does not provide medical advice,diagnosis or treatment.Get additional information.© 2005 – 2023 Everyday Health, Inc., a Ziff Davis company. Everyday Health is among the federally registered trademarks of Everyday Health, Inc. and may not be used by third
0 Comments
The addition of pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) for the first-line treatment of patients with persistent, recurrent, or metastatic cervical cancer continues to result in significant survival benefits, according to a presentation at the recent American Society of Clinical Oncology (ASCO) annual meeting. MedPage Today brought together three expert leaders in
0 Comments
Intense exercise may increase stroke risk among patients with moderate or severe stenosis, new research suggests. Investigators simulated blood flow in a sophisticated computational model of the internal carotid artery (ICA) at three stages of stenosis ― without blockage, with mild (30%) blockage, and with moderate (50%) blockage. They compared the effect of exercise-induced elevated
0 Comments
Allergy drop immunotherapy does not make you sleepy. Some allergy symptom-relievers, like Benadryl, list drowsiness as a side effect, so you need to be thoughtful about when you take them. But, disease-modifying treatment like allergy drops, or sublingual immunotherapy, does not – because the ingredients are simple. The only ingredients in allergy drops following the
0 Comments
FDA Approves Roctavian (valoctocogene roxaparvovec-rvox) Gene Therapy for Adults with Severe Hemophilia A SAN RAFAEL, Calif., June 29, 2023 /PRNewswire/ — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that the United States Food and Drug Administration (FDA) approved Roctavian™ (valoctocogene roxaparvovec-rvox) gene therapy for
0 Comments
New study shows that long-term disinvestment in health and wealth resources in historically redlined neighborhoods likely contributes to a disproportionate rate of kidney failure among Black adults today. Living in a historically redlined neighborhood may increase residents’ chances of experiencing kidney failure in the United States, particularly for Black people, according to a new study
0 Comments
CAMBRIDGE, Mass., June 29, 2023. Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced topline results from IMPACT, a Phase 4 collaborative study investigating the impact of Auryxia (ferric citrate), when used as the primary phosphate-lowering therapy, on the utilization of erythropoiesis-stimulating agent
0 Comments
Eating Earlier in the Day Can Improve Blood Sugar Levels, Study Finds – Diabetes Daily Learning Center Learning Center: LearningCenter Diabetes Daily does not provide medical advice,diagnosis or treatment.Get additional information.© 2005 – 2023 Everyday Health, Inc., a Ziff Davis company. Everyday Health is among the federally registered trademarks of Everyday Health, Inc. and may
0 Comments
The FDA approved valoctocogene roxaparvovec (Roctavian) as the first gene therapy for the treatment of adults with severe hemophilia A, drug developer Biomarin announced on Thursday. Patients with severe disease are eligible for the one-time, single-dose treatment if they don’t have antibodies to adeno-associated virus serotype 5 (AAV5), as detected by an FDA-approved test. FDA
0 Comments
The US Food and Drug Administration approved the gene therapy valoctocogene roxaparvovec (Roctavian, BioMarin) for adults with severe hemophilia A. Valoctocogene roxaparvovec, a one-time, single-dose IV infusion, is the first gene therapy approved in the United States for severe hemophilia A and will cost around $2.9 million. BioMarin has said the price tag reflects “the
0 Comments
Alex Zhavoronkov, left, founder and CEO of Insilico Medicine, and Feng Ren, co-CEO and chief scientific officer, at the company’s robotics lab in Suzhou, China. Source: Insilico Medicine The first drug fully generated by artificial intelligence entered into clinical trials with human patients this week. Insilico Medicine, a Hong Kong-based biotech startup with more than
0 Comments